Management of Myasthenia Gravis: The Interplay of Family Practice, Nursing, Lab Diagnoses, Emergency Response, and Dental Care
DOI:
https://doi.org/10.22399/ijcesen.4628Keywords:
Myasthenia Gravis, management, multidisciplinary approach, family practice, nursing, lab diagnosticsAbstract
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The management of MG requires a comprehensive, multidisciplinary approach that encompasses family practice, nursing, lab diagnostics, emergency response, and dental care. Family practitioners play a critical role in initiating diagnosis and coordinating care through regular follow-ups and symptom management. They often collaborate with neurologists and other specialists to optimize treatment plans tailored to each patient’s unique needs. Education on managing the disease, recognizing crises, and adhering to reinforcements of medications is essential to ensure patient stability and quality of life. In this collaborative framework, nursing professionals serve as vital points of contact for patient care, monitoring vital signs, managing medication regimens, and providing emotional support. Lab diagnostics, including antibody testing and imaging studies, are crucial for accurate diagnosis and monitoring disease progression. In emergency scenarios, prompt recognition of myasthenic crises is essential, requiring a well-structured emergency response protocol to ensure patient safety. Additionally, dental care should not be overlooked, as some MG patients may face challenges related to oral health due to muscle weakness and medication side effects. Dentists must work in coordination with the healthcare team to address any dental issues while ensuring that treatment plans respect the patient’s overall health status and medication regimen, thereby fostering a seamless, integrated management approach for those living with Myasthenia Gravis.
References
[1] Kupersmith M.J., Moster M., Bhuiyan S., Warren F., Weinberg H. Beneficial Effects of Corticosteroids on Ocular Myasthenia Gravis. Arch. Neurol. 1996;53:802–804.
[2] Walker M.B. Treatment of myasthenia gravis with physostigmine. Lancet. 1934;223:1200–1201.
[3] Fateh-Moghadam A., Wick M., Besinger U., Geursen R.G. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;323:848–849.
[4] Schlezinger N.S., Fairfax W.A. Evaluation of Ocular Signs and Symptoms in Myasthenia Gravis. Arch. Ophthalmol. 1959;62:985–990.
[5] Vrinten C., Van Der Zwaag A.M., Weinreich S.S., Scholten R.J., Verschuuren J.J. Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes. Cochrane Database Syst. Rev. 2014;2014:CD010028.
[6] Chelmicka-Schorr E., Wollmann R.L., Kwasniewski M.N., Kim D.H., Dupont B.L. The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG) Int. J. Immunopharmacol. 1993;15:19–24.
[7] Prinscott J. Preanesthetic Assessment 1. Birkhäuser; Boston, MA, USA: 1988. The Patient with Myasthenia Gravis; pp. 109–116.
[8] Grob D., Brunner N., Namba T., Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141–149.
[9] Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., Spitler L.E. Plasmapheresis and Immunosuppressive Drug Therapy in Myasthenia Gravis. N. Engl. J. Med. 1977;297:1134–1140.
[10] Walker M.B. Case showing the Effect of Prostigmin on Myasthenia Gravis. Proc. R. Soc. Med. 1935;28:759–761.
[11] Vanhaesebrouck A.E., Webster R., Maxwell S., Rodriguez Cruz P.M., Cossins J., Wickens J., Liu W.W., Cetin H., Cheung J., Ramjattan H., et al. Beta2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure. Brain. 2019;142:3713–3727.
[12] Soliven B., Rezania K., Gundogdu B., Harding-Clay B., Oger J., Arnason B.G. Terbutaline in myasthenia gravis: A pilot study. J. Neurol. Sci. 2009;277:150–154.
[13] Pope C., Karanth S., Liu J. Pharmacology and toxicology of cholinesterase inhibitors: Uses and misuses of a common mechanism of action. Environ. Toxicol. Pharmacol. 2005;19:433–446.
[14] Kupersmith M.J., Latkany R., Homel P. Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis. Arch. Neurol. 2003;60:243–248.
[15] Sheikh S., Alvi U., Soliven B., Rezania K. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J. Clin. Med. 2021;10:1537.
[16] Osserman K.E. Progress report on mestinon bromide (pyridostigmine bromide) Am. J. Med. 1955;19:737–739.
[17] Prado M.B., Jr., Adiao K.J. Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies. Neurocritical Care. 2021;35:528–544.
[18] Ippoliti G., Cosi V., Piccolo G., Lombardi M., Mantegaz R., Devathasan G., Kueh Y., Chong P. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;324:809–810.
[19] Mertens H.G., Balzereit F., Leipert M. The Treatment of Severe Myasthenia Gravis with Immunosuppressive Agents. Eur. Neurol. 1969;2:321–339.
[20] Grob D. Course and management of myasthenia gravis. J. Am. Med. Assoc. 1953;153:529–532.
[21] Gajdos P., Outin H., Elkharrat D., Brunel D., de Rohan-Chabot P., Raphael J., Goulon M., Goulon-Goeau C., Morel E. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;323:406–407.
[22] Campbell H.B.E. Myasthenia gravis pseudoparalytica: Review of 70 case reports, including nine new patients. Brain. 1900;23:277–336.
[23] Tether J.E. Treatment of myasthenia gravis with mestinon bromide. J. Am. Med. Assoc. 1956;160:156–158.
[24] Grob D., Namba T. Corticotropin in generalized myasthenia gravis. Effect of short, intensive courses. JAMA. 1966;198:703–707.
[25] Blalock A., Mason M.F., Morgan H.J., Riven S.S. Myasthenia Gravis and Tumors of the Thymic Region: Report of a Case in Which the Tumor Was Removed. Ann. Surg. 1939;110:544–561.
[26] Chelmicka-Schorr E., Checinski M.E., Arnason B.G. Sympathetic nervous system and PC12 pheochromocytoma-derived factors suppress stimulation of lymphocytes. Brain Behav. Immun. 1990;4:23–29.
[27] Osserman K.E., Kornfeld P., Cohen E., Genkins G., Mendelow H., Goldberg H., Windsley H., Kaplan L.I. Studies in myasthenia gravis; review of two hundred eighty-two cases at the Mount Sinai Hospital, New York City. AMA Arch. Intern. Med. 1958;102:72–81.
[28] Newsom-Davis J., Wilson S., Vincent A., Ward C. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979;313:464–468.
[29] Macfarlane J.W. Myasthenia Gravis: Its Treatment by a Combination of Prostigmin and Glycine-Ephedrine Therapy. Glasg. Med. J. 1937;128:7–11.
[30] Kennedy F.S., Moersch F.P. Myasthenia Gravis: A Clinical Review of Eighty-Seven Cases Observed between 1915 and the Early Part of 1932. Can. Med. Assoc. J. 1937;37:216–223.
[31] Randall L.O., Conroy C.E., Ferruggia T.M., Kappell B.H., Knoeppel C.R. Pharmacology of the anticholinesterase drugs; mestinon, prostigmin, tensilon and TEPP. Am. J. Med. 1955;19:673–678.
[32] Laurent L.P.E. Clinical Observations on the Use of Prostigmin in the Treatment of Myasthenia Gravis. Br. Med. J. 1935;1:463–465.
[33] Osserman K.E., Teng P., Kaplan L.I. Studies in myasthenia gravis; preliminary report on therapy with mestinon bromide. J. Am. Med. Assoc. 1954;155:961–965.
[34] Wolfe G.I., Kaminski H., Aban I.B., Minisman G., Kuo H.C., Marx A., Ströbel P., Mazia C., Oger J., Cea J.G., et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N. Engl. J. Med. 2016;375:511–522.
[35] Harvey A.M., Lilienthal J.L., Talbot S.A. Observations on the Nature of Myasthenia Gravis. The Effect of Thymectomy on Neuro-Muscular Transmission. J. Clin. Investig. 1942;21:579–588.
[36] Westerberg M.R., Magee K.R. Mestinon in the Treatment of Myasthenia Gravis. Neurology. 1954;4:762–772.
[37] Al-Haidar M., Benatar M., Kaminski H.J. Ocular myasthenia. Neurol. Clin. 2018;36:241–251.
[38] Pinching A.J., Peters D.K. Remission of myasthenia gravis following plasma-exchange. Lancet. 1976;2:1373–1376.
[39] Kohm A.P., Sanders V.M. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol. Rev. 2001;53:487–525.
[40] Sussman J., Farrugia M.E., Maddison P., Hill M., Leite M.I., Hilton-Jones D. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract. Neurol. 2015;15:199–206.
[41] Mayer S.A., Thomas C.E. Therapy of Myasthenic Crisis. Crit. Care Med. 1998;26:1136–1137.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
